臨床検査50巻7号

2006年07月発行

今月の主題 ホルマリン固定パラフィン包埋標本からどこまで遺伝子検索は可能か？ 話題

CISH(chromogenic in situ hybridization)の有効性と問題点

著者： 熊本裕行¹

所属機関： ¹東北大学大学院歯学研究科口腔病態外科学講座口腔病理学分野

ページ範囲：P.793 - P.797

　1．はじめに

　近年の分子生物学の進歩を背景に，形態学を主とする病理組織診断においても，形態変化の所見のみではなく，その基盤となる遺伝子や蛋白質などの変化の理解が求められるようになってきている^1,2)．CISH(chromogenic in situ hybridization)は，蛍光色素や放射性同位元素を使わずDABやBCIP/NBTなどの発色原(chromogen)を用いて，組織標本上でDNAやmRNAを検出するin situ hybridization(ISH)であり，通常は蛍光色素を用いてDNA観察を蛍光顕微鏡下で行うFISH(fluorescence in situ hybridization)と対比されることが多い^3～5)．

　本稿では病理組織検体を用いたCISHにより，病因・病態形成の理解を通じ診断や治療方針などの臨床応用が可能と思われるものについて概説する．

参考文献

　１) Stass SA, Mixson J：Oncogenes and tumor suppressor genes：therapeutic implications. Clin Cancer Res　3：2687-2695, 1997

　２) Kumamoto H：Molecular pathology of odontogenic tumors. J Oral Pathol Med　35：65-74, 2006

　３) Tanner M, Gancberg D, Di Leo A, et al：Chromogenic in situ hybridization：a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol　157：1467-1472, 2000

　４) Kumamoto H, Sasano H, Taniguchi T, et al：Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma：application in screening of patients for trastuzumab (Herceptin(R)) therapy. Pathol Int　51：579-584, 2001

　５) Terry J, Barry TS, Horsman DE, et al：Fluorescence in situ hybridization for the detection of t(X；18)(p11.2；q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe. Diagn Mol Pathol　14：77-82, 2005

　６) Rummukainen JK, Salminen T, Lundin J, et al：Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest　81：1545-1551, 2001

　７) Tsai HY, Hsi BL, Hung IJ, et al：Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas：a chromogenic in situ hybridization study in paraffin sections. Hum Pathol　35：1397-1403, 2004

　８) Awaya H, Takeshima Y, Furonaka O, et al：Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridization and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol　58：1076-1080, 2005

　９) Tanner M, Hollmen M, Junttila TT, et al：Amplification of HER-2 in gastric carcinoma：association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol　16：273-278, 2005

　10) Dandachi N, Dietze O, Hauser-Kronberger C：Chromogenic in situ hybridization：a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest　82：1007-1014, 2002

　11) Zhao J, Wu R, Au A, et al：Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol　15：657-665, 2002

　12) Gupta D, Middleton LP, Whitaker MJ, et al：Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol　119：381-387, 2003

　13) Park K, Kim J, Lim S, et al：Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol　16：937-943, 2003

　14) Savinainen KJ, Saramaki OR, Linja MJ, et al：Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol　160：339-345, 2002

　15) Lassus H, Leminen A, Vayrynen A, et al：ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol　92：31-39, 2004

　16) Peiro G, Mayr D, Hillemanns P, et al：Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol　17：227-287, 2004

　17) Marquez A, Wu R, Zhao J, et al：Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISHTM) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol　13：1-8, 2004

　18) Bhargava R, Gerald WL, Li AR, et al：EGFR gene amplification in breast cancer：correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol　18：1027-1033, 2005

　19) Lambros MB, Simpson PT, Jones C, et al：Unlocking pathology archives for molecular genetic studies：a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest　86：398-408, 2006

　20) Rabbitts TH：Chromosomal translocations in human cancer. Nature　372：143-149, 1994

　21) Bennicelli JL, Barr FG：Chromosomal translocations and sarcomas. Curr Opin Oncol　14：412-419, 2002

　22) Tkachuk DC, Westbrook CA, Andreeff M, et al：Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science　250：559-562, 1990

　23) Lishner M, Kenet G, Lalkin A, et al：Fluorescent in situ hybridization for the detection of t (8：14) in Burkitt's lymphoma. Acta Haematol　90：186-189, 1993

　24) Taylor C, Patel K, Jones T, et al：Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t (11；22) using fluorescence in situ hybridisation. Br J Cancer　67：128-133, 1993

　25) Matsumura K, Kallioniemi A, Kallioniemi O, et al：Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res　52：3474-3477, 1992

　26) Sauter G, Deng G, Moch H, et al：Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol　144：756-766, 1994

　27) Schwemmle M, Clemens MJ, Hilse K, et al：Localization of Epstein-Barr virus-encoded RNAs EBER-1 and EBER-2 in interphase and mitotic Burkitt lymphoma cells. Proc Natl Acad Sci USA　89：10292-10296, 1992

　28) Straus SE, Cohen JI, Tosato G, et al：Epstein-Barr virus infections：biology, pathogenesis, and management. Ann Intern Med　118：45-58, 1993

　29) Jacquemier J, Penault F, Durst M, et al：Detection of five different human papillomavirus types in cervical lesions by in situ hybridization. A study of 110 cases using sulfonated probes. Hum Pathol　21：911-917, 1990

　30) Van Ranst M, Kaplan JB, Burk RD：Phylogenetic classification of human papillomaviruses：correlation with clinical manifestations. J Gen Virol　73：2653-2660, 1992

　31) 熊本裕行，清水良央，大家清：舌粘膜上皮増殖性疾患とヒト乳頭腫ウイルス(HPV)感染の相関性について-非放射性in situ hybridization(non-RI ISH)法．東北歯誌　12：87-91, 1993

　32) Segal GH, Shick HE, Tubbs RR, et al：In situ hybridization analysis of lymphoproliferative disorders. Assessment of clonality by immunoglobulin light-chain messenger RNA expression. Diagn Mol Pathol　3：170-177, 1994

　33) Handa K, Yamakawa M, Takeda H, et al：Expression of cell cycle markers in colorectal carcinoma：superiority of cyclin A as an indicator of poor prognosis. Int J Cancer　84：225-233, 1999

　34) Kumamoto H, Kimi K, Ooya K：Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med　30：309-315, 2001